China’s NRDL: The World’s Largest Market Access Event Is Underway
Every year, one event stands out in the market access calendar like no other, China’s National Reimbursement Drug List (NRDL). With the 2025 application window now closed, the race is on for companies vying to secure access to the world’s largest single-payer market. Inclusion means reaching over 1.3 billion people making the NRDL not just a policy tool, but the largest market access opportunity on the planet. And in 2025, the rules are shifting again. The NRDL is no longer just a list; it's a dynamic platform driven by increasingly rigorous Health Technology Assessments (HTAs) and new dual-track reimbursement models that are transforming how and which innovations make it to Chinese patients. This article explains why the NRDL process is more important than ever, what’s changing in 2025, and how companies should rethink their strategy to align with China’s evolving dual-track reimbursement model. China’s Market: From Emerging to Essential The strategic importance of the NRDL is roo...
